4DMT to Participate in Upcoming Investor Conferences
4DMT announced management presentations at three major healthcare investor conferences in September 2026. The company reported completion of enrollment for its lead product 4D-150 Phase 3 trial (4FRONT-2) for wet AMD with topline data expected in H2 2027, and positive 2-year data from the 4D-150 PRISM trial. 4D-710, the company's genetic medicine for cystic fibrosis, continues development.